WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announces plans to invest $2 billion to expand its long-standing manufacturing footprint in Maryland. This includes a significant expansion of its flagship biologics manufacturing facility in Frederick and construction of a new state-of-the-art facility in Gaithersburg for the development and clinical supply of innovative molecules to be used in clinical trials. The investment will support 2,600 jobs across the two sites in the state includin. ...

This story was originally published on Manufacturing Dive. To receive daily news and insights, subscribe to our free daily Manufacturing Dive newsletter. Dive Brief: Pharmaceutical giant Novartis said it will create a flagship manufacturing hub in North Carolina in an effort to produce all of its medicines from start to finish in the United States. Total investment is expected to be $771 million, according to a news release from Gov. Josh Stein. The Switzerland-based company’s plans for Durham and Morr ...

Core Viewpoint - Eli Lilly plans to invest over $1.2 billion to expand its manufacturing site in Puerto Rico to increase U.S. production capacity and mitigate potential tariff risks [1] Company Summary - The investment of more than $1.2 billion indicates Eli Lilly's commitment to enhancing its manufacturing capabilities [1] - The expansion aims to bolster U.S. production capacity, reflecting a strategic move in response to potential trade challenges [1] Industry Summary - The decision to expand manufacturing in Puerto Rico highlights a trend among pharmaceutical companies to localize production to avoid tariffs and supply chain disruptions [1]

Core Insights - Eli Lilly plans to invest over $1 billion in India to enhance manufacturing and supply capabilities through local drugmakers [1] Investment Strategy - The investment aims to leverage India's skilled workforce to improve production efficiency and meet growing demand [1] Market Expansion - This move is part of Eli Lilly's strategy to expand its presence in the Indian market, which is increasingly important for global pharmaceutical companies [1]

Wabtec has unveiled plans to expand its manufacturing facility in Barton, as part of its strategy to increase production capacity and consolidate core activities in the UK rail sector. The 7,300m² expansion is scheduled for completion in the fourth quarter of 2026 and will create 150 skilled jobs in the region. The Barton site will accommodate up to 500 employees upon completion and support several product lines supplying components to rail operators and manufacturers across the UK. Lichfield MP Dave ...